单倍体造血细胞移植作为自然杀伤细胞免疫治疗平台
本综述探讨了采用移植后环磷酰胺的单倍体造血细胞移植作为自然杀伤(NK)细胞免疫治疗平台的潜力与适用性。文中讨论了供者来源NK细胞可体外大量扩增、细胞因子激活可能增强NK细胞体内持久性与疗效,以及移植后输注NK细胞可改善高危和/或复发髓系恶性肿瘤结局而不增加移植物抗宿主病、严重细胞因子释放综合征或神经毒性风险。
要点
- 单倍体造血细胞移植联合移植后环磷酰胺可作为NK细胞免疫治疗的平台。
- 供者来源NK细胞可体外大量扩增,细胞因子激活可能增强其体内持久性与疗效。
- 移植后输注NK细胞可改善高危和/或复发髓系恶性肿瘤结局,不增加移植物抗宿主病、严重细胞因子释放综合征或神经毒性风险。
核心结论
- 单倍体造血细胞移植联合移植后环磷酰胺是NK细胞免疫治疗的合适平台,相关策略的初步结果 promising,可能快速转化为临床应用。
研究设计与样本
- 本综述探讨了采用移植后环磷酰胺的单倍体造血细胞移植作为NK细胞免疫治疗平台的关键方面。
主要发现
- 供者来源NK细胞可体外大量扩增。
- 细胞因子激活可能增强NK细胞体内持久性与疗效。
- 移植后输注NK细胞可改善高危和/或复发髓系恶性肿瘤结局,且不增加移植物抗宿主病、严重细胞因子释放综合征或神经毒性风险。
关键数值与推荐
- 细胞因子激活的NK细胞可与免疫调节剂协同和/或经基因工程改造以增强肿瘤靶向特异性、细胞毒性和持久性并防止耗竭。
临床怎么用
- 作者认为,细胞因子激活的NK细胞可与免疫调节剂协同和/或经基因工程改造以增强肿瘤靶向特异性、细胞毒性和持久性并防止耗竭。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An innovative approach is crucially needed to manage relapse after allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematological malignancies. This review explores key aspects of haploidentical HCT with post-transplant cyclophosphamide, highlighting the potential and suitability of this platform for natural killer (NK) cell immunotherapy. NK cells, known for their unique abilities to eliminate cancer cells, can also exhibit memory-like features and enhanced cytotoxicity when activated by cytokines. By discussing promising results from clinical trials, the review delves into the recent major advances: donor-derived NK cells can be expanded ex vivo in large numbers, cytokine activation may enhance NK cell persistence and efficacy in vivo, and post-HCT NK cell infusion can improve outcomes in high-risk and/or relapsed myeloid malignancies without increasing the risk of graft-versus-host disease, severe cytokine release syndrome, or neurotoxicity. Looking ahead, cytokine-activated NK cells can be synergized with immunomodulatory agents and/or genetically engineered to enhance their tumor-targeting specificity, cytotoxicity, and persistence while preventing exhaustion. The ongoing exploration of these strategies holds promising preliminary results and could be rapidly translated into clinical applications for the benefit of the patients.
引用
- Duléry R, Piccinelli S, Beg MS, et al. Haploidentical hematopoietic cell transplantation as a platform for natural killer cell immunotherapy. Am J Hematol. 2024. PMID: 39248561. doi:10.1002/ajh.27471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。